Absci (ABSI) to Release Earnings on Tuesday

Absci (NASDAQ:ABSI) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 12th. Analysts expect Absci to post earnings of ($0.19) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Absci (NASDAQ:ABSI) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Absci had a negative return on equity of 44.24% and a negative net margin of 2,838.89%. The company had revenue of $1.27 million for the quarter, compared to analyst estimates of $2.05 million. During the same quarter last year, the company earned ($0.27) EPS. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Absci Trading Up 1.0 %

Shares of NASDAQ ABSI opened at $4.07 on Monday. Absci has a 1-year low of $1.18 and a 1-year high of $6.72. The company has a 50-day moving average of $3.99 and a two-hundred day moving average of $4.09. The company has a market cap of $462.19 million, a PE ratio of -4.38 and a beta of 2.18. The company has a current ratio of 6.49, a quick ratio of 6.49 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ABSI shares. Guggenheim initiated coverage on shares of Absci in a research report on Wednesday, October 2nd. They issued a “buy” rating and a $10.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Absci in a research report on Thursday, August 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $8.67.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.